Article
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Clinical pharmacology and therapeutics - 1 Mar 2011
Relling M V, Gardner E E, Sandborn W J, Schmiegelow K, Pui C-H, Yee S W, Stein C M, Carrillo M, Evans W E, Klein T E
Abstract excerpt
Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population)...
Topics
- Antimetabolites, Antineoplastic
- Azathioprine
- Dose-Response Relationship, Drug
- Genotype
- Humans
- Immunosuppressive Agents
- Mercaptopurine
- Methyltransferases
- Thioguanine